FDA Approves Asundexian to Reduce Repeat Stroke Risk in Certain Adults

Stroke prevention can protect both lifespan and independence, especially after a first event. According to this FDA announcement, Sunharbo, the drug asundexian, is now approved alongside medicines that stop platelets from clumping together. It is intended for adults after a recent mild to moderate ischemic stroke caused by a clot outside the heart, or after a high risk temporary episode.

The approval rests on OCEANIC-STROKE, a randomized trial involving 12,327 adults. Participants started asundexian or placebo within 72 hours of symptoms, and both groups received antiplatelet therapy. Taking 50 milligrams daily reduced ischemic stroke risk by 26% relative to placebo over a median 14.2 months. The announcement does not provide absolute event rates, preventing calculation of the absolute benefit here.

Asundexian blocks factor XIa, a protein involved in blood clotting. Its potential appeal is additional protection against clots without a large overall increase in major bleeding. However, similar overall bleeding rates do not mean equal safety for everyone. Major bleeding increased among patients older than 75 and during the first 90 days; gastrointestinal bleeding was also more common with treatment.

For eligible stroke survivors, the practical step is a discussion with their treating clinician, not starting medication independently. Treatment selection requires reviewing bleeding history, liver function, other medicines, and planned procedures. Certain interacting drugs, including carbamazepine, can reduce effectiveness. The announcement recommends withholding treatment around elective procedures and after clot dissolving therapy, with timing and management directed by medical professionals.

This is not an approval for stroke prevention in atrial fibrillation, and it does not establish longer life or slower aging. Diarrhea was the most frequently reported adverse reaction. Moderate or severe liver impairment makes treatment unsuitable under the announcement's recommendations. The complete prescribing information and trial publication are needed to assess absolute benefits, subgroup risks, and detailed safety findings.